About trevi therapeutics inc - TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.
TRVI At a Glance
Trevi Therapeutics, Inc.
195 Church Street
New Haven, Connecticut 06510
| Phone | 1-203-304-2499 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -42,759,000.00 | |
| Sector | Health Technology | Employees | 34 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
TRVI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 8.766 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -30.481 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.001 |
TRVI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,257,617.647 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
TRVI Liquidity
| Current Ratio | 19.659 |
| Quick Ratio | 19.659 |
| Cash Ratio | 19.311 |
TRVI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -28.083 |
| Return on Equity | -30.23 |
| Return on Total Capital | -23.239 |
| Return on Invested Capital | -30.103 |
TRVI Capital Structure
| Total Debt to Total Equity | 0.411 |
| Total Debt to Total Capital | 0.409 |
| Total Debt to Total Assets | 0.389 |
| Long-Term Debt to Equity | 0.243 |
| Long-Term Debt to Total Capital | 0.242 |